๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors

โœ Scribed by A. Awada; A. Hendlisz; T. Gil; B. Schwartz; S. Bartholomeus; E. Brendel; D. de Valeriola; C. Haase; T. Delaunoit; M. Piccart

Book ID
118621563
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
147 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I Clinical and Pharmacokinetic Stu
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
โœ Strumberg, D. ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› American Society of Clinical Oncology ๐ŸŒ English โš– 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.